MBX Biosciences, Inc. Overview
Pro stress-test →MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies designed to overcome key limitations of current peptide therapies.
Strategic Profile
Pro stress-test →The company reported positive Phase 2 topline results for once-weekly canvuparatide in hypoparathyroidism, with a 63% responder rate at 12 weeks and 79% at six months in the open-label extension. With $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, management expects this will fund operations into 2029.
Competitive Landscape
Pro stress-test →10 analysts recommend buying the stock, while 1 suggest selling, with an average 12-month price target of $61.10 (range $18-$88). MBX competes in the precision peptide/GLP-1 space alongside larger players like Novo Nordisk and Eli Lilly, but differentiates through proprietary prodrug technology targeting underserved endocrine indications rather than competing directly on obesity blockbuster drugs.
Industry Context
MBX Biosciences, Inc. operates in Biopharmaceuticals - Precision Peptide Therapeutics.
Key facts
Founded: 2018 · Headquarters: Carmel, Indiana · Employees: 43 · Revenue: Pre-commercial (clinical stage) · Market cap: $1.65B